AKCOME vs Suniva - solar panel manufacturer comparison

Suniva is a US-based solar cell and module manufacturer headquartered in Norcross, Georgia, originally spun out of Georgia Tech in 2007. After filing for Chapter 11 bankruptcy in 2017 - unable to compete against lower-cost Asian imports - the company re-emerged under new ownership and restarted production at its Georgia plant in 2024 with an initial capacity of approximately 1 GW, with expansion plans targeting 2.5 GW at that site and a separate 4.5 GW facility in Laurens, South Carolina expected to open by 2027. Its panels carry Buy American compliance with over 80% US content. AKCOME (Jiangsu Akcome Science and Technology Co.) is a Chinese manufacturer with production bases across Suzhou, Ganzhou, Huzhou, and Zhoushan, and reported HJT cell and module capacity exceeding 13 GW. AKCOME holds Bloomberg Tier 1 status, reflecting established bankability with project finance lenders, while Suniva's institutional track record is still being rebuilt after its years-long production gap. On overall manufacturing scale and lender recognition, AKCOME currently holds the stronger position.

Suniva's restarted line centers on PERC crystalline silicon cells and modules, making it most relevant to US utility and commercial projects where domestic content requirements or Inflation Reduction Act incentives apply. AKCOME has staked its technology identity on HJT (heterojunction), one of the more advanced cell architectures currently in mass production, and its portfolio is reported as entirely bifacial HJT with modules reaching outputs around 730 W and module efficiencies that independent reviewers place in the 21-22.5% range. That combination suits utility-scale ground mounts and space-constrained commercial rooftops where bifacial energy yield and premium efficiency carry weight.

For buyers outside the United States in 2025, AKCOME is the more straightforward choice - it offers proven bankability, a technically advanced HJT line, and broad international availability. Suniva's value proposition is primarily domestic: US buyers navigating federal procurement rules or IRA adder credits will find its American-made cells genuinely competitive. The two brands are not direct substitutes - they occupy distinct niches defined more by geography and policy context than by head-to-head performance differences.

Generated by Claude Sonnet · 2026-06-08